MAP2K7 and melanoma: This finding made the RAS-RAF-MEK-MAPK pathway the most promising target in melanoma research and led to the development of targeted therapy against mutated BRAFV600 which resulted in a treatment-breakthrough with impressive clinical responses and significant prolongation of progression-free-survival (PFS) and OS in the majority of advanced melanoma patients in clinical trials [13–16].